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acting in those pathways and processes that develop the car- 
tilage and then help maintain the tissue throughout life? Sub- 
sequent genome-wide linkage and association studies have re- 
vealed genes whose proteins do regulate cartilage development 
and homeostasis. Three particularly compelling results are: 1) 
an association to the secreted frizzled-related protein 3 (SFRP3) 
gene FRZB on chromosome 2q32.1 in a UK population [2], 
2) an association to the asporin gene ASPN on chromosome 
9q22.31 in a Japanese population [3] and 3) an association to 
the calmodulin 1 gene CALM1 on chromosome 14q32.11, also in 
a Japanese population [4]. SFRP3, asporin and calmodulin 1 all 
regulate chondrogenesis and help to maintain the cartilage ma- 
trix. However, they do this through distinct pathways: SFRP3 acts 
as an antagonist of extracellular Wnt ligands; asporin influences 
TGF-I~-mediated signalling; calmodulin 1 influences intracellular 
calcium signalling. 
These recent genetic findings suggest that OA genetic risk is act- 
ing on chondrocyte differentiation, proliferation and the general 
homeostatic balance of the articular cartilage ECM rather than 
through an inadequately constructed cartilage ECM. This is an 
important observation since signalling pathways are modifiable. 
The new genetics has therefore identified targets for new drug 
development as well as loci that can now be genotyped to iden- 
tify at-risk individuals for more focussed clinical trials. 
In this talk I shall bring the listener up-to-date with the recent 
breakthroughs and offer a sober assessment of the position of 
the field and what steps need to be taken to ensure these break- 
throughs are exploited for patient benefit. 
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IMAGING IN OSTEOARTHRITIS: TRANSLATIONAL 
RESEARCH APPLICATIONS OF FUNCTIONAL 
CARTILAGE MRI 
Timothy J. Mosher 
Purpose: To review functional techniques for MRI of articular car- 
tilage and present results of recent studies on in viva biomechan- 
ics 
Description: The ability to non-invasively image articular carti- 
lage makes MRI a valuable tool in the study of osteoarthritis. 
Of particular promise are translational research applications that 
bridge basic science studies in animals or tissue samples with 
clinical studies in humans. Given the central role of joint biome- 
chanics in the pathogenesis of OA and difficulty replicating hu- 
man joint biomechanics with animal models, there is growing in- 
terest in developing MRI techniques that are sensitive to changes 
in cartilage when placed under physiologic loads. This presenta- 
tion will review new functional cartilage MRI techniques that have 
been applied to in viva study of human cartilage biomechanics, 
including quantitative cartilage morphometry, delayed gadolinium 
enhanced MRI of Cartilage (DGEMRIC), and cartilage T2 map- 
ping. Recent results demonstrate regional response of cartilage 
to load bearing exercise with greater compressibility near the ar- 
ticular surface. Results obtained from MRI will be compared with 
current understanding of cartilage biomechanics derived from ex 
vivo testing. 
Conclusion: Current MRI techniques demonstrate sensitivity to 
changes in cartilage morphology and biochemical content that 
occur in response to physiological oading conditions. These 
techniques provide new translational research opportunities for 
evaluating the role of altered biomechanics in the pathogenesis 
of OA. 
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EVALUATING PAIN IN OSTEOARTHRITIS 
Maxime Dougados 
The collection of variables such as the level of pain in os- 
teoarthritic (OA) patients might have different purposes but the 
most important is to facilitate a therapeutical decision. 
For this purpose (to make a therapeutical decision), the following 
points have to be considered: 
1. Which pain? 
Pain might be related to the activity (inflammation) or the sever- 
ity (structural damage) or both. Pain occurring during the sec- 
ond part of the night is considered as reflecting an inflammatory 
process. At variance, pain, occurring after physical activities, is 
considered as reflecting a structural damage. Therefore, it is rec- 
ommended to collect separately these two variables. 
2. Pain of the target pain or of the OA patient? 
Localized OA is quite rare. Therefore, even in case of the evalua- 
tion of a single ("target") joint, it is sometimes difficult o differenti- 
ate pain related to this "target" joint to the one related to other OA 
affected joints. For clinical trials, FDA (Food and Drugs Adminis- 
tration) has recommended to use 2~variables: one evaluating the 
"target" joint and another one evaluating the "other OA" joints. 
3. Which anatomical lesion is responsible of pain? 
Pain might be related to an "articular" anatomical esion (carti- 
lage, sub-chondral bone, synovial membrane) but also to peri- 
articular lesion such as tendinitis. 
4. Clinical trials versus daily practice 
During clinical trials, the systematic use of specific tools such as 
VAS Visual Analogue Scale or NRS (Numerical Rating Scale) has 
been fully validated. The use of such tools (instead of the con- 
ventional "how are you doing") has not proven its utility in daily 
practice. 
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OBESITY AND OSTEOARTHRITIS 
Michele M Hooper 
Obesity (BMI _> 30 kg/m 2) is increasing worldwide. In the United 
States, 28% of adult men and 34% of women are obese. There 
is a high prevalence of painful musculoskeletal symptoms in up- 
per and lower extremities in the obese that improve with weight 
loss, including physical function and quality of life. There is a 
modest association between obesity and hand, hip and patello- 
femoral OA but a very strong association with (tibio-femoral) knee 
OA (kOA). Risk ratios for radiographic kOA increase with weight, 
even in normal BMI range and weight loss protects against kOA 
development. Mechanisms of the effect of BMI on kOA include; 
metabolic abnormalities, genetics, malalignment (varus/valgus), 
laxity, meniscectomy, ACL tears, bone density, muscle mass and 
gait biomechanics. Obesity and kOA have moderate degrees of 
heritability, but not through shared genes. Female gender and 
aging are associated with increased fat mass, decreased mus- 
cle mass and increased kOA. Bone density is higher in obesity; 
